Welichem is Participating in BioPartnering North America Conference in February, 2008

    BURNABY, BC, Feb. 1 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), is pleased to announce that a team of five delegates from the
Company will attend the 6th Annual BioPartnering North America (BPN)
Conference, which will be held at the Westin Bayshore Resort and Marina in
Vancouver, B.C., Canada on February 4 to 6, 2008.
    BPN is North America's most innovative partnering conference for life
science innovators and investors, and is supported by leading pharmaceutical,
biotechnological, financial and service companies from around the world. It
offers one of the best networking opportunities with business development
executives and will be attended by over 800 delegates from more than 500
    Welichem will feature an Open House Podium Presentation and one Open
House Booth Presentation to showcase its two promising drug candidates.
WBI-1001, a unique anti-inflammatory compound currently in clinical trials, is
shown to be effective in treating psoriasis and eczema from its preliminary
test results. WBI-2100, on the other hand, has shown strong efficacy in
targeting solid tumours as well as in boosting neutrophil level. The Company's
team will have face-to-face meetings with over a dozen large
pharmaceutical/biotech companies to pursue licensing and partnering
opportunities for drug development and commercialization.

    About Welichem Biotech Inc.

    Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.

    York Yingping Guo
    President and Chief Executive Officer

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements. The Company thus seeks safe harbour.

    %SEDAR: 00021386E

For further information:

For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
yorkguo@welichem.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: investors@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890